In recent years, mRNA in lipid nanoparticles (mRNA–LNPs) has emerged as a promising strategy for treating numerous conditions, including COVID-19, various cancers and chronic genetic disorders. To ...

Lipid nanoparticles, or LNPs, are best known as the delivery system used in the COVID-19 mRNA vaccines given to billions of people worldwide. Scientists are now exploring their potential far beyond ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

Researchers from the Perelman School of Medicine have developed an mRNA vaccine with the potential to prevent life-threatening allergic reactions. The new vaccine, described in an article published in ...

Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.

Scientists at the University of Chicago have built a lipid nanoparticle system that delivers mRNA directly to ...

Lipid nanoparticles (LNPs) act as carriers for mRNA and CRISPR payloads across a wide range of therapeutic applications, from cancer to inflammatory and genetic diseases. The same delivery system used ...

Lipid nanoparticles, such as the one shown in this illustration, are used as vehicles to deliver mRNA-based vaccines. The U.S. Department of Health and Human Services announced on Tuesday that it will ...

U.S. mRNA Therapeutics Market is estimated at USD 6.85 billion in 2025 and is expected to reach USD 33.04 billion by 2035 owing to the extensive biotechnology infrastructure in the countryAustin, ...

The American College of Physicians (ACP) has recommended that adults aged 65 years or older receive updated 2025–2026 mRNA-based COVID-19 vaccines, according to February guidelines published in Annals ...

The future of mRNA medicine in the U.S. rests on many "ifs," and the worst-case scenario may not come to pass. But in the face of staggering uncertainty, researchers in the field are starting to look ...